Skin Cancer PBMC
Skin Cancer PBMC samples are cryopreserved from donors with clinically confirmed skin cancer. Ideal for tumour immunology: T-cell exhaustion and checkpoint receptor profiling, TCR repertoire sequencing, ex vivo checkpoint blockade, and single-cell immune profiling across melanoma, basal cell carcinoma, and cutaneous squamous cell carcinoma. Subtype, stage, and treatment status annotated.
Skin Cancer PBMC for Immuno-Oncology Research
Skin Cancer PBMC samples are cryopreserved peripheral blood mononuclear cells from IRB-consented donors with a clinically confirmed skin cancer diagnosis. Cells are processed within 24 hours of collection and preserved in CryoStor® CS10 to support tumour immunology research across melanoma, basal cell carcinoma, and cutaneous squamous cell carcinoma.
Skin Cancer Tumour Immunology and Why PBMC
Skin cancer is a neoplastic disease. Its subtypes arise from different cells of origin and carry different mutational and immunological profiles, and the systemic immune compartment is central to how they are now treated:
- Ultraviolet radiation is the dominant carcinogen, leaving a characteristic UV mutational signature and giving melanoma and cutaneous squamous cell carcinoma among the highest tumour mutational burdens of any cancer
- Subtype-defining drivers differ: BRAF and NRAS mutations in melanoma, hedgehog pathway activation through PTCH1 in basal cell carcinoma, and TP53 with high UV-driven mutation load in squamous cell carcinoma
- High neoantigen load makes these tumours immunogenic, which is why immune checkpoint blockade against PD-1, PD-L1, and CTLA-4 has been transformative in advanced melanoma and cutaneous squamous cell carcinoma
- Systemic T-cell state matters. Circulating T-cell subsets, exhaustion markers such as PD-1, TIM-3, and LAG-3, and myeloid populations are studied as correlates of checkpoint inhibitor response and immune-related adverse events
- Immunosuppression is a risk factor — solid organ transplant recipients have markedly increased squamous cell carcinoma incidence, underlining the role of immune surveillance in cutaneous carcinogenesis
- Why PBMC: immunophenotyping, T-cell receptor repertoire sequencing, antigen-specific T-cell expansion, ex vivo checkpoint blockade, and single-cell profiling are all performed on cryopreserved patient PBMCs
Donor Stratification Available
- Histological subtype: melanoma, basal cell carcinoma, or cutaneous squamous cell carcinoma
- Stage and extent of disease, including localised versus metastatic
- Treatment status: treatment-naive, post-surgical, or on checkpoint inhibitor or targeted therapy
- Treatment response category and progression status where documented
- Immunosuppressed donors, including transplant recipients, where available
- Age, sex assigned at birth, race/ethnicity, and Fitzpatrick skin type
- Matched healthy controls available
Product Features
- Research Use Only (RUO), cryopreserved skin cancer PBMC samples
- Clinically confirmed skin cancer donors, with histological subtype annotated
- Available in cell counts ranging from 5 million to 2 billion
- Processed within 24 hours of collection
- Preserved using CryoStor® CS10 freezing media
- IRB-approved protocols and electronic informed consent
- Screening (LeukoLot™) available prior to bulk orders
De-identified Donor Data
- Verified skin cancer diagnosis
- Donor demographics: age, sex assigned at birth, race/ethnicity
- Self-reported allergies and infectious disease history
- Additional skin cancer subtype, staging, and treatment data available on request
Applications
- Immunophenotyping of T-cell, NK, and myeloid populations in skin cancer
- T-cell exhaustion and checkpoint receptor expression profiling
- Ex vivo checkpoint blockade and immune agonist pharmacology
- T-cell receptor repertoire sequencing and clonality analysis
- Antigen-specific T-cell expansion and functional cytotoxicity assays
- Cell therapy and engineered T-cell process development using patient-derived cells
- Single-cell RNA sequencing and multi-omic immune profiling
- Biomarker discovery for immunotherapy response and immune-related toxicity
Other Skin Cancer Specimen Types
- Skin Cancer Leukopak — apheresis-derived, for high cell-number requirements
- Skin Cancer Serum — for circulating protein and cytokine biomarkers
- Skin Cancer Whole Blood — fresh, for same-day assays and genotyping
- Melanoma PBMC — for a melanoma-specific cohort
- Solid Tumor Cancer PBMC — for broader oncology cohorts
Compliance and Quality Assurance
- IRB-approved collections and protocols
- 21 CFR Part 11-compliant e-consent
- HIPAA-compliant donor data protection
Ordering & Customization
Skin Cancer PBMC samples ship on dry ice in standard or custom aliquots. For pricing, international orders, or regulatory documentation, contact learnmore@sanguinebio.com. Browse all human PBMCs or request a custom disease-state collection.
Protocols & Documentation
-
Download
PBMC Isolation from Whole Blood
Standard operating procedure for isolating peripheral blood mononuclear cells from whole blood using density-gradient separation.
-
Download
Immune Cell Isolation
Guidelines for isolating immune cell populations with validated enrichment steps, purity checkpoints, and documentation.
-
Download
Choosing the Right PBMC Configuration
Reference guide comparing PBMC formats, cryopreservation states, and study-fit recommendations for your application.
-
Download
Thawing Cryopreserved PBMC
Validated thawing protocol to recover viable cryopreserved PBMCs while minimizing activation and loss of function.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
PBMC
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – all our products are research use only (RUO).
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom PBMC cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.